grey glp-1 The weight loss revolution | Feature Akston Initiates Clinical Trial of

Phase 3 programmes also evaluated long-term safety, tolerability, and metabolic outcomes, forming the basis for subsequent regulatory approvals in certain jurisdictions

The drugs have become household names.

Results Each propensity-score matched group constituted 3424 patients, 45% women, 21% had a history of cardiovascular disease, and 13.9% were treated with sodium-glucose cotransporter-2 inhibitors at baseline

Patent law is only one part of a much broader equation.The growing burden of diabetes across Africa provides an opportunity to rethink how intellectual property, public health and industrial policy interact before the continent faces another access crisis.The legal tools already exist.The more difficult question is whether governments are prepared to use them and whether the international community is willing to support a model of pharmaceutical innovation that rewards research while recognising that access to essential medicines is, ultimately, a matter of public interest.This is a co-published article, originally published on WIPR.

GLP-1 medications have become one of the most talked-about tools for weight loss and diabetes managementbut there's much more to the story